Plus   Neg

Cummins Expects 2018 Revenues To Be Up 4% To 8%

Cummins Inc. (CMI) said that it expects full year 2018 revenues to be up 4 to 8 percent, and Earnings Before Interest, Taxes, Depreciation and Amortization or EBITDA to be in the range of 15.8 to 16.2 percent of sales. EBITDA for the full year 2017 was 15.0 percent of sales, excluding the impact of US tax reform.

"We expect demand to remain strong in many of our core markets in 2018 and profitability to improve as a result of higher sales and continued execution of our cost reduction initiatives. The Company again plans to return at least 50 percent of Operating Cash Flow to shareholders in 2018," said Chairman and CEO Tom Linebarger.

Net loss attributable to the company in the fourth quarter was $274 million or $1.65 per share, compared to net income of $378 million ($2.25 per diluted share). Fourth quarter net income included $777 million in one-time charges related to tax reform. Excluding the tax reform impact, net income attributable to Cummins in the fourth quarter was $503 million or $3.03 per share, reflecting a 19.5 percent tax rate.

Fourth quarter revenues of $5.5 billion increased 22 percent from the same quarter in 2016.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
U.S. auto safety regulator has opened an investigation into about 115,000 Tesla electric vehicles over a front suspension safety issue. The probe covers 2015 through 2017 Model S sedans and 2016 through 2017 Model X SUVs. The investigation comes after Tesla reportedly started a recall over the issue for vehicles in China. Santa Cruz Bicycles LLC has recalled certain model year 2020 bicycles with aluminum frames citing fall risks, according to the U.S. Consumer Product Safety Commission. The recall involves about 2,900 units of model year 2020 Auminum Santa Cruz and Juliana Bicycles. In addition, about 216 were sold in Canada. AstraZeneca is mulling an additional global trial to confirm the 90% efficacy rate of its Covid-19 vaccine candidate at lower dosage, Bloomberg news quoted Chief Executive Officer Pascal Soriot as saying. In an interview, Soriot noted that instead of adding the trial to an ongoing U.S. process, the company might launch a fresh study to evaluate efficacy of lower dosage of its vaccine that perform
Follow RTT